Menopause

CBIH Charts Path to Future Leadership in Cannabis Medicine

A letter from our desk HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Since the start of the year, Cannabis Bioscience…

2 years ago

Daré Bioscience Announces Reverse Stock Split

Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) --…

2 years ago

Talkspace and Labcorp’s Ovia Health Form Women’s Health Coalition to Deliver Accessible, Affordable Solutions to Address Women’s Diverse Health Needs

Conceive, Evernow, FitOn, Nurx, Cove, and Nutrium Join as Founding Members to Support the Coalition’s Focus on Expanding Access to…

2 years ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ETDevelopment Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive…

2 years ago

ARC Fertility Named Finalist for Two Categories at FemTech World Awards 2024

CUPERTINO, Calif.--(BUSINESS WIRE)--ARC Fertility (ARC), a highly experienced national provider of innovative fertility and family-forming benefits for self-insured employers and…

2 years ago

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today…

2 years ago

The Fibroid Foundation Announces National Menstrual Health Awareness Month

May is National Menstrual Health Awareness Month - May 28 is International Menstrual Hygiene DayROCKVILLE, MD / ACCESSWIRE / May…

2 years ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré joins a nationwide network working to accelerate transformative health solutionsSAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience,…

2 years ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA…

2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Conference Call and Webcast Today at 4:30 p.m. ET2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2%…

2 years ago